Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19

 Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19

Regeneron’s Eylea (aflibercept) Injection Receives the US FDA’s Approval as a Prefilled Syringe

Shots:

  • The P-III trial involves assessing REGN-COV2 with an expected enrollment of 2000 patients at 100 sites which will be evaluated to prevent infection among uninfected people who have had close exposure to a COVID-19 patient
  • REGN-COV2 is also being evaluated in P-II/III portion of two P-I/II/III trials testing the cocktail’s ability to treat hospitalized (N= 1,850) and non-hospitalized (N=1050) patients with COVID-19 across 150 sites in the US, Brazil, Mexico, and Chile with expected results in late summer. Additionally, clinical progress follows positive recommendations from IDMC of P-I trial which involved assessing of REGN-COV2 in 30 hospitalized and non-hospitalized patients with COVID-19   
  • REGN-COV2 is double-antibody cocktail developed using VelociMab and manufacturing capabilities for the prevention and treatment of COVID-19

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post